Total Payments
$21,153
2024 Payments
$2,140
Companies
3
Transactions
35
Medicare Patients
3,034
Medicare Billing
$259,379
Payment Breakdown by Category
Consulting$13,248 (62.6%)
Other$4,525 (21.4%)
Travel$2,918 (13.8%)
Food & Beverage$436.96 (2.1%)
Education$25.61 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $13,248 | 5 | 62.6% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $4,525 | 7 | 21.4% |
| Travel and Lodging | $2,918 | 9 | 13.8% |
| Food and Beverage | $436.96 | 11 | 2.1% |
| Education | $25.61 | 3 | 0.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. | $19,644 | 29 | $0 (2024) |
| United Therapeutics Corporation | $1,496 | 5 | $0 (2023) |
| Genentech USA, Inc. | $12.31 | 1 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $2,140 | 1 | Boehringer Ingelheim Pharmaceuticals, Inc. ($2,140) |
| 2023 | $8,005 | 15 | Boehringer Ingelheim Pharmaceuticals, Inc. ($7,882) |
| 2022 | $968.52 | 3 | Boehringer Ingelheim Pharmaceuticals, Inc. ($968.52) |
| 2021 | $3,093 | 5 | Boehringer Ingelheim Pharmaceuticals, Inc. ($1,720) |
| 2020 | $1,300 | 1 | Boehringer Ingelheim Pharmaceuticals, Inc. ($1,300) |
| 2019 | $12.31 | 1 | Genentech USA, Inc. ($12.31) |
| 2018 | $5,634 | 9 | Boehringer Ingelheim Pharmaceuticals, Inc. ($5,634) |
All Payment Transactions
35 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 09/24/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | OFEV (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $2,139.58 | General |
| Category: RESPIRATORY | ||||||
| 11/09/2023 | Boehringer Ingelheim Pharmaceuticals, Inc. | OFEV (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $556.10 | General |
| Category: RESPIRATORY | ||||||
| 11/09/2023 | United Therapeutics Corporation | — | Food and Beverage | In-kind items and services | $123.11 | General |
| 10/10/2023 | Boehringer Ingelheim Pharmaceuticals, Inc. | OFEV (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $556.10 | General |
| Category: RESPIRATORY | ||||||
| 10/10/2023 | Boehringer Ingelheim Pharmaceuticals, Inc. | OFEV (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $556.10 | General |
| Category: RESPIRATORY | ||||||
| 06/22/2023 | Boehringer Ingelheim Pharmaceuticals, Inc. | OFEV (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $238.96 | General |
| Category: RESPIRATORY | ||||||
| 06/22/2023 | Boehringer Ingelheim Pharmaceuticals, Inc. | OFEV (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $238.96 | General |
| Category: RESPIRATORY | ||||||
| 06/08/2023 | Boehringer Ingelheim Pharmaceuticals, Inc. | OFEV (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $238.96 | General |
| Category: RESPIRATORY | ||||||
| 05/10/2023 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Travel and Lodging | In-kind items and services | $115.00 | General |
| 05/10/2023 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $35.00 | General |
| 03/17/2023 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Travel and Lodging | In-kind items and services | $531.80 | General |
| 03/17/2023 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Travel and Lodging | In-kind items and services | $349.88 | General |
| 03/17/2023 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $40.00 | General |
| 01/03/2023 | Boehringer Ingelheim Pharmaceuticals, Inc. | OFEV (Drug) | Consulting Fee | Cash or cash equivalent | $4,250.00 | General |
| Category: RESPIRATORY | ||||||
| 01/03/2023 | Boehringer Ingelheim Pharmaceuticals, Inc. | OFEV (Drug) | Travel and Lodging | In-kind items and services | $140.00 | General |
| Category: RESPIRATORY | ||||||
| 01/03/2023 | Boehringer Ingelheim Pharmaceuticals, Inc. | OFEV (Drug) | Food and Beverage | In-kind items and services | $35.00 | General |
| Category: RESPIRATORY | ||||||
| 12/09/2022 | Boehringer Ingelheim Pharmaceuticals, Inc. | OFEV (Drug) | Travel and Lodging | In-kind items and services | $721.82 | General |
| Category: RESPIRATORY | ||||||
| 12/09/2022 | Boehringer Ingelheim Pharmaceuticals, Inc. | OFEV (Drug) | Travel and Lodging | In-kind items and services | $207.19 | General |
| Category: RESPIRATORY | ||||||
| 12/09/2022 | Boehringer Ingelheim Pharmaceuticals, Inc. | OFEV (Drug) | Food and Beverage | In-kind items and services | $39.51 | General |
| Category: RESPIRATORY | ||||||
| 10/08/2021 | United Therapeutics Corporation | — | Consulting Fee | Cash or cash equivalent | $1,347.50 | General |
| 10/06/2021 | United Therapeutics Corporation | TYVASO (Drug) | Education | In-kind items and services | $2.50 | General |
| Category: PAH | ||||||
| 09/21/2021 | United Therapeutics Corporation | TYVASO (Drug) | Education | In-kind items and services | $20.61 | General |
| Category: PAH | ||||||
| 08/03/2021 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,720.00 | General |
| 02/22/2021 | United Therapeutics Corporation | TYVASO (Drug) | Education | In-kind items and services | $2.50 | General |
| Category: PAH | ||||||
| 08/25/2020 | Boehringer Ingelheim Pharmaceuticals, Inc. | OFEV (Drug) | Consulting Fee | Cash or cash equivalent | $1,300.00 | General |
| Category: RESPIRATORY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 17 | 851 | 1,132 | $399,260 | $75,251 |
| 2022 | 12 | 691 | 960 | $285,299 | $53,703 |
| 2021 | 13 | 650 | 917 | $297,827 | $63,065 |
| 2020 | 19 | 842 | 1,106 | $324,248 | $67,360 |
Total Patients
3,034
Total Services
4,115
Medicare Billing
$259,379
Procedure Codes
64
All Medicare Procedures & Services
64 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 85 | 121 | $53,526 | $11,286 | 21.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 45 | 77 | $47,822 | $9,754 | 20.4% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 39 | 102 | $37,536 | $8,519 | 22.7% |
| 94729 | Test to examine how well the lungs exchange gases | Office | 2023 | 128 | 175 | $46,252 | $7,454 | 16.1% |
| 94375 | Test to measure rate of airflow | Office | 2023 | 166 | 234 | $58,851 | $6,834 | 11.6% |
| 90677 | Pneumococcal conjugate vaccine, 20 valent (pcv20), for intramuscular use | Office | 2023 | 24 | 24 | $23,364 | $5,916 | 25.3% |
| 94726 | Test to determine lung volumes using sensors | Office | 2023 | 100 | 112 | $27,495 | $4,780 | 17.4% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2023 | 15 | 25 | $23,602 | $4,077 | 17.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 59 | 66 | $20,790 | $3,957 | 19.0% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 24 | 25 | $16,316 | $3,451 | 21.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 19 | 19 | $10,830 | $2,449 | 22.6% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 13 | 13 | $9,858 | $2,280 | 23.1% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 16 | 18 | $8,326 | $1,762 | 21.2% |
| 94618 | Test for exercise-induced lung stress | Office | 2023 | 29 | 32 | $4,880 | $860.48 | 17.6% |
| G0009 | Administration of pneumococcal vaccine | Office | 2023 | 21 | 21 | $2,613 | $640.92 | 24.5% |
| 94060 | Test to measure expiratory airflow and volume changes before and after medication administration | Office | 2023 | 16 | 16 | $2,816 | $463.50 | 16.5% |
| G0008 | Administration of influenza virus vaccine | Office | 2023 | 14 | 14 | $1,774 | $427.28 | 24.1% |
| 94375 | Test to measure rate of airflow | Facility | 2023 | 20 | 20 | $1,883 | $214.51 | 11.4% |
| 94729 | Test to examine how well the lungs exchange gases | Facility | 2023 | 18 | 18 | $726.00 | $126.00 | 17.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 93 | 149 | $62,330 | $13,001 | 20.9% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 51 | 118 | $39,157 | $9,301 | 23.8% |
| 94729 | Test to examine how well the lungs exchange gases | Office | 2022 | 110 | 141 | $35,570 | $5,969 | 16.8% |
| 94375 | Test to measure rate of airflow | Office | 2022 | 137 | 196 | $46,697 | $5,283 | 11.3% |
| 94726 | Test to determine lung volumes using sensors | Office | 2022 | 103 | 134 | $31,076 | $5,144 | 16.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 55 | 70 | $20,596 | $4,262 | 20.7% |
About Dr. Srihari Veeraraghavan, M.D
Dr. Srihari Veeraraghavan, M.D is a Pulmonary Disease healthcare provider based in Atlanta, Georgia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/05/2006. The National Provider Identifier (NPI) number assigned to this provider is 1891704375.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Srihari Veeraraghavan, M.D has received a total of $21,153 in payments from pharmaceutical and medical device companies, with $2,140 received in 2024. These payments were reported across 35 transactions from 3 companies. The most common payment nature is "Consulting Fee" ($13,248).
As a Medicare-enrolled provider, Veeraraghavan has provided services to 3,034 Medicare beneficiaries, totaling 4,115 services with total Medicare billing of $259,379. Data is available for 4 years (2020–2023), covering 64 distinct procedure/service records.
Ad
Practice Information
- Specialty Pulmonary Disease
- Other Specialties Critical Care Medicine
- Location Atlanta, GA
- Active Since 08/05/2006
- Last Updated 09/10/2015
- Taxonomy Code 207RP1001X
- Entity Type Individual
- NPI Number 1891704375
Products in Payments
- OFEV (Drug) $16,852
- TYVASO (Drug) $25.61
- Xolair (Biological) $12.31
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Pulmonary Disease Doctors in Atlanta
Dr. Colin Swenson, M.d, M.D
Pulmonary Disease — Payments: $198,668
Pulmonary Disease $198,668
Gregory Martin, M.d, M.D
Pulmonary Disease — Payments: $98,374
Pulmonary Disease $98,374
Jesse Roman, M.d, M.D
Pulmonary Disease — Payments: $78,820
Pulmonary Disease $78,820
Victor Tseng, M.d, M.D
Pulmonary Disease — Payments: $55,025
Pulmonary Disease $55,025
Dr. Venkatesh Lakshminarayanan, Md, MD
Pulmonary Disease — Payments: $37,215
Pulmonary Disease $37,215
Matthew Schmitt, M.d, M.D
Pulmonary Disease — Payments: $21,211
Pulmonary Disease $21,211